On Wednesday, Yingli Green Energy Hold. Co. Ltd. (ADR) (NYSE:YGE)’s shares inclined 1.74% to $1.17.
Yingli Green Energy Hold. Co. Ltd. (ADR) (YGE) declared that it has supplied 1.1 megawatts (MW) of solar panels for Venezuela’s largest solar project, a hybrid solar-diesel power plant located in Los Roques. The 1.1 MW solar farm was developed, engineered, and constructed by Consorcio Energias Limpias Alternativas Venezolanas (CELAV). Vico Export Solar Energy, a major regional solar product distributor, offered logistical and operational support for equipment procurement.
This power plant is Yingli’s first large-scale project in Venezuela: until recently, the Venezuelan market was concentrated in off-grid systems of 25 kilowatts (kW) and smaller, typically located in isolated regions. As the country’s inaugural PV power plant, it contains more than 4,400 multicrystalline YGE Series solar panels. They are predictable to generate over 1,400 megawatt-hours (MWh) per year, which is enough energy to power over 400 typical Venezuelan homes. The system began operating in May 2015.
Yingli Green Energy Holding Company Limited, together with its auxiliaries, designs, develops, markets, manufactures, sells, and installs photovoltaic (PV) products in the People’s Republic of China and internationally. The company offers polysilicon ingots and blocks, polysilicon wafers, PV cells, PV modules, and integrated PV systems; and develops and operates solar projects.
Violin Memory Inc (NYSE:VMEM)’s shares dropped -3.51% to $2.75.
Violin Memory Inc (VMEM) which has witnessed a noteworthy price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in VMEM.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 1 estimate moving down in the past 30 days, contrast with no upward revision. This trend has caused the consensus estimate to trend lower, widening from a loss of 24 cents a share a month ago to its current level of a loss of 28 cents.
Also, for the current quarter, Violin Memory has seen 1 downward estimate revision as compared to no revision in the opposite direction, dragging the consensus estimate down to a loss of $1.10 a share from a loss of 95 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 15.6% in the past month.
Violin Memory, Inc. develops and supplies memory-based storage systems to bring storage performance in line with high-speed applications, servers, and networks worldwide. The company provides flash storage platforms and all flash arrays that integrate enterprise-class hardware and software technologies to address the limitations of hard disk drive-based and solid state drive-based storage solutions that use off-the-shelf components.
At the end of Wednesday’s trade, Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)‘s shares surged 6.37% to $2.84.
Actinium Pharmaceuticals Inc (ATNM) declared recently the closing of its formerly declared registered direct offering of $5.0 million of its common stock. Under the terms of the subscription agreements, the Company issued an aggregate of 1,923,078 shares of the Company’s common stock at a purchase price of $2.60 per share. This financing was led by investor Dr. Phillip Frost.
Actinium anticipates using the net proceeds for general corporate purposes, counting capital expenditures, the advancement of our product candidates in clinical trials, such as Iomab™-B and Actimab-A, preclinical trials, to support licensing activities, and to meet working capital needs.
Laidlaw & Company (UK) Ltd. acted as the sole placement agent with respect to the offering.
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies. Its products comprise Actimab-A, an antibody-drug construct, which comprises monoclonal antibody Lintuzumab and alpha emitting radioisotope actinium 225; and is in multicenter Phase I/II clinical trials for acute myeloid leukemia (AML). The company also offers Iomab-B, an antibody-drug construct that comprises the BC8 monoclonal antibody and beta emitting radioisotope iodine 131, and is used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications.
Endo International plc - Ordinary Shares (NASDAQ:ENDP), ended its Wednesday’s trading session showed no change, and closed at $82.40.
Endo International plc - Ordinary Shares (ENDP) declared the closing of its formerly declared registered offering of ordinary shares (the “Offering”). Following the Offering, the Company issued 27,627,628 ordinary shares, counting 3,603,603 ordinary shares sold upon the exercise in full by the underwriters of their option to purchase additional ordinary shares from the Company, at a price of $83.25 per share, for aggregate gross proceeds of about $2.3 billion.
The Company anticipates to use the net proceeds of the Offering, together with the proceeds of additional indebtedness and cash on hand, to fund the formerly declared acquisition of Par Pharmaceutical Holdings, Inc. (“Par”), in addition to repayments of indebtedness of Par and certain transaction expenses. The Company intends to use any remaining proceeds for general corporate purposes, counting acquisitions and debt repayments. If the Par acquisition is not consummated, the Company plans to use the net proceeds of the Offering for general corporate purposes, counting acquisitions and debt repayments.
Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals segment provides various branded prescription products, counting Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Fortesta Gel, Supprelin LA, Valstar, Vantas, Sumavel DosePro, Aveed, and Natesto to treat and manage pain and conditions in urology, endocrinology, and oncology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
